Back to Agendas
Communicating Pharmaceutical Risks and Benefits: Why Is It So Hard and How Can We Do Better?
Session Chair(s)
Brian Edwards, DrMed
Vice President
International Society of Pharmacovigilance, United Kingdom
Pharmaceuticals are developed for patients who behave according to perceptions, not just facts, about medicines. How should we respond to demands for higher quality information, greater openness and transparency with round-the-clock media scrutiny? What is the role of trust and how can we strengthen trustworthiness in communication? How should the evidence behind good communication impact regulatory processes? How can we assess whether communication is effective in changing behavior? Questions like these will be discussed in this forum as we aim to address this core risk minimization activity for any pharmaceutical organization.
Learning Objective : Discuss the established principles of effective communication; Identify hurdles and solutions for effective communication; Define regulatory feedback from marketing authorization holder (MAH) activities.
Speaker(s)
Risk Communication: Time For a New Approach Yet Again
Brian Edwards, DrMed
International Society of Pharmacovigilance, United Kingdom
Vice President
Communicating Benefits and Risks of Medicines: Challenges and Opportunities
Dinah Duarte, MSc
European Medicines Agency, Netherlands
Signal Management Lead
Risk-Benefit Communications of Medicines Based on Advances in Cognitive Behavioral Science Research
Sweta Chakraborty, PhD
Institute on Science for Global Policy (ISGP), United States
Associate Director
Have an account?